Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
A respiratory disease characterized by interstitial lung disease (often with pulmonary hemorrhage) and inflammatory arthritis, associated with high-titer autoantibodies (including anti-nuclear and anti-neutrophil cytoplasmic antibodies, and rheumatoid factor). Patients present from infancy to adolescence with tachypnea, cough, hemoptysis, and/or joint pain. Some patients may also develop glomerular disease.
Features include always present findings: Hemosiderin-laden macrophages in bronchoalveolar fluid, Restrictive ventilatory defect, and Abnormal lung tissue (abnormal pulmonary interstitial morphology); and very common findings: Joint inflammation (arthritis). 15 total HPO annotations.
Organ System | Phenotype Count | Example Features |
|---|---|---|
Lungs and breathing | 5 | Hemosiderin-laden macrophages in bronchoalveolar fluid, Dyspnea, Restrictive ventilatory defect |
Phenotype severity distribution: 3 always present features, 1 very common feature, 3 common features.
Estimated prevalence: <1 in 1,000,000 (VERY_RARE).
No clinical trials have been registered for autoimmune interstitial lung disease-arthritis syndrome.
36 publications have been identified in PubMed for autoimmune interstitial lung disease-arthritis syndrome. Research spans Case Report / Case Series (36%), Review / Meta-Analysis (31%), and Other (14%).
Research Type | Count | % of Total |
|---|---|---|
Patient case studies | 13 | 36% |
Data assembled from 5 of 12 sources · Last updated Sep 20, 2026, 8:43 AM UTC
Online Mendelian Inheritance in Man
European rare disease database
Genetic and Rare Diseases Info Center
Common questions about autoimmune interstitial lung disease-arthritis syndrome
Lab test results | 2 | Antinuclear antibody positivity, Elevated CRP (inflammation marker) (elevated circulating c-reactive protein concentration) |
Bones and joints | 2 | Arthralgia, Joint inflammation (arthritis) |
Kidneys and urinary system | 1 | Crescentic glomerulonephritis |
Age of onset: childhood.
Research summaries
11 |
31% |
Other research | 5 | 14% |
Laboratory research | 5 | 14% |
Disease patterns and progression | 2 | 6% |
Gonsard A (2026). [PMID: 41904028](https://pubmed.ncbi.nlm.nih.gov/41904028/). *Paediatr Respir Rev*. [Review / Meta-Analysis]
Triaille C (2026). [PMID: 41932423](https://pubmed.ncbi.nlm.nih.gov/41932423/). *Am J Kidney Dis*. [Case Report / Case Series]
Taguchi T (2026). [PMID: 41718982](https://pubmed.ncbi.nlm.nih.gov/41718982/). *Subcell Biochem*. [Review / Meta-Analysis]
David C (2026). [PMID: 41395910](https://pubmed.ncbi.nlm.nih.gov/41395910/). *Ann Rheum Dis*. [Epidemiology / Natural History]
Velu PP (2026). [PMID: 42222885](https://pubmed.ncbi.nlm.nih.gov/42222885/). *J Clin Invest*. [Review / Meta-Analysis]
Avouac J (2026). [PMID: 41763596](https://pubmed.ncbi.nlm.nih.gov/41763596/). *Joint Bone Spine*. [Other]
Shum AK (2026). [PMID: 41501213](https://pubmed.ncbi.nlm.nih.gov/41501213/). *Nat Rev Rheumatol*. [Review / Meta-Analysis]
de Groen PC (2026). [PMID: 41355193](https://pubmed.ncbi.nlm.nih.gov/41355193/). *Immunology*. [Review / Meta-Analysis]
David C (2026). [PMID: 41805977](https://pubmed.ncbi.nlm.nih.gov/41805977/). *J Exp Med*. [Basic Science / Preclinical]
Unknown (2026). [PMID: 41885200](https://pubmed.ncbi.nlm.nih.gov/41885200/). *Pediatr Pulmonol*. [Other]
AI-curated news mentioning autoimmune interstitial lung disease-arthritis syndrome
Updated Aug 19, 2026
Expanded Access Programs (EAPs) provide patients with serious illnesses, like autoimmune lung disease, access to investigational treatments when standard options fail. Patients must meet specific eligibility criteria, including physician endorsement of potential benefits over risks.